Dr Amphlett and Dr Lutz have played central roles in establishing ImmunoGen’s product development capabilities. These functions complement the company’s research capabilities in ImmunoGen’s advancement of its own new anticancer compounds and the target-to-commercial product expertise.
After joining ImmunoGen in 2001, Dr Amphlett has lead a team with expertise in the many areas including process development, formulation development, characterisation and analytical methods for both the individual product components as well as for the complete drug product.
Before joining ImmunoGen, Dr Amphlett took up responsibility at Genetics Institute, a part of Pfizer and at Revlon Health Care’s subsidiary, Armour Pharmaceuticals.
Since joining ImmunoGen as a scientist in 1992, Dr Lutz took up many resposibilities. After getting promoted to senior director of preclinical development in 2004 and to executive director of preclinical development in 2007, Dr Lutz lead the company’s preclinical development functions. In early 2010 he became executive director of drug development at ImmunoGen.
Dr Lutz leads functions that provide support necessary for advancing ImmunoGen and partner new product candidates from research through clinical development.
Daniel Junius, president and CEO of ImmunoGen, said: “Over the past few years, Bob and Godfrey have led the transformation of functions that enable us to successfully build and advance our proprietary product pipeline as well as provide support to our partners.”